KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Xenon Pharmaceuticals (XENE) Return on Sales (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Return on Sales for 12 consecutive years, with 46.12% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Sales changed N/A to 46.12% in Q4 2025 year-over-year; TTM through Dec 2025 was 46.12%, a N/A change, with the full-year FY2025 number at 46.12%, changed N/A from a year prior.
  • Return on Sales was 46.12% for Q4 2025 at Xenon Pharmaceuticals, down from 41.51% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 2.24% in Q1 2022 to a low of 1240.4% in Q2 2023.
  • A 4-year average of 141.01% and a median of 25.53% in 2022 define the central range for Return on Sales.
  • Peak YoY movement for Return on Sales: skyrocketed 137bps in 2022, then plummeted -118227bps in 2023.
  • Xenon Pharmaceuticals' Return on Sales stood at 6.84% in 2021, then crashed by -94bps to 13.29% in 2022, then tumbled by -9234bps to 1240.4% in 2023, then surged by 96bps to 46.12% in 2025.
  • Per Business Quant, the three most recent readings for XENE's Return on Sales are 46.12% (Q4 2025), 41.51% (Q3 2025), and 37.76% (Q2 2025).